
|Videos|October 24, 2022
Dr. Rana McKay on practice-changing trials in advanced renal cell carcinoma
Author(s)Urology Times staff
Rana McKay, MD, says the CheckMate-214, KEYNOTE-426, CheckMate-9ER, and CLEAR trials have revolutionized the first-line treatment paradigm in advanced renal cell carcinoma.
Advertisement
Rana McKay, MD, describes the CheckMate-214, KEYNOTE-426, CheckMate-9ER, and CLEAR trials, which she says, “have largely changed the way we treat kidney cancer in the modern era for patients with advanced/metastatic disease.” McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Treatment Selection in Advanced Prostate Cancer
3
Annual ACS NCDB report details national trends in prostate cancer care
4
Advice for the Next Generation of Urologists in mCSPC Management
5





